Standout Papers

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inh... 2021 2026 2022 2024214
  1. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (2021)
    Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology

Citation Impact

59 standout
Sub-graph 1 of 21

Citing Papers

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
2 intermediate papers

Works of Stuart Turner being referenced

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2021 Standout

Author Peers

Author CCM PRM Oncology Last Decade Papers Cites
Stuart Turner 360 321 182 42 1.0k
Justin M. Wolter 4 1 9 19 366
H. H. Boer 10 5 12 36 1.1k
Paulo Casal 1 1 9 627
Curtis S. Cooper 8 801
Jeongin Seo 11 179

All Works

Loading papers...

Rankless by CCL
2026